A detailed history of Morgan Stanley transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 110,016 shares of DMAC stock, worth $531,377. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110,016
Previous 86,200 27.63%
Holding current value
$531,377
Previous $254,000 81.1%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.8 - $4.49 $66,684 - $106,933
23,816 Added 27.63%
110,016 $460,000
Q2 2024

Oct 17, 2024

SELL
$2.16 - $3.66 $11,605 - $19,665
-5,373 Reduced 5.87%
86,200 $254,000
Q2 2024

Aug 14, 2024

SELL
$2.16 - $3.66 $11,605 - $19,665
-5,373 Reduced 5.87%
86,200 $254,000
Q1 2024

Oct 17, 2024

BUY
$2.58 - $3.23 $13,862 - $17,354
5,373 Added 6.23%
91,573 $253,000
Q1 2024

Aug 16, 2024

SELL
$2.58 - $3.23 $75,908 - $95,033
-29,422 Reduced 24.32%
91,573 $253,000
Q1 2024

May 15, 2024

SELL
$2.58 - $3.23 $75,908 - $95,033
-29,422 Reduced 24.32%
91,573 $253,000
Q4 2023

Aug 16, 2024

BUY
$2.05 - $2.99 $71,329 - $104,037
34,795 Added 40.37%
120,995 $343,000
Q4 2023

Feb 13, 2024

BUY
$2.05 - $2.99 $55,749 - $81,313
27,195 Added 28.99%
120,995 $343,000
Q3 2023

Nov 15, 2023

BUY
$2.56 - $4.4 $93,952 - $161,480
36,700 Added 64.27%
93,800 $242,000
Q2 2023

Aug 14, 2023

SELL
$1.53 - $4.4 $134 - $387
-88 Reduced 0.15%
57,100 $246,000
Q1 2023

May 15, 2023

BUY
$1.32 - $1.89 $2,622 - $3,755
1,987 Added 3.6%
57,188 $87,000
Q4 2022

Feb 14, 2023

BUY
$1.13 - $1.62 $2,479 - $3,554
2,194 Added 4.14%
55,201 $87,000
Q3 2022

Nov 14, 2022

BUY
$1.2 - $2.07 $6,248 - $10,778
5,207 Added 10.89%
53,007 $66,000
Q2 2022

Oct 27, 2022

BUY
$1.86 - $2.62 $26,741 - $37,667
14,377 Added 43.02%
47,800 $96,000
Q2 2022

Aug 15, 2022

BUY
$1.86 - $2.62 $26,741 - $37,667
14,377 Added 43.02%
47,800 $96,000
Q1 2022

Oct 27, 2022

SELL
$2.29 - $3.88 $32,923 - $55,782
-14,377 Reduced 30.08%
33,423 $84,000
Q1 2022

May 13, 2022

BUY
$2.29 - $3.88 $21,807 - $36,949
9,523 Added 39.85%
33,423 $84,000
Q4 2021

Feb 14, 2022

BUY
$3.43 - $4.65 $42,875 - $58,125
12,500 Added 109.65%
23,900 $89,000
Q3 2021

Nov 15, 2021

BUY
$3.1 - $4.32 $35,340 - $49,248
11,400 New
11,400 $46,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $128M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.